Search 

Amorphex Therapeutics is an early clinical stage company that was founded to develop products for sustained ophthalmic drug delivery using patented TODDD™ technology. Topical ophthalmic pharmaceuticals are a $5+Billion market, but inaccurate and inefficient delivery systems, poor compliance and excessive side effects undermine their clinical benefits and true sales potential. TODDD™ is a soft, non-invasive device that is completely concealed under the eyelid and continuously delivers therapeutic levels of drug 24/7 over several months. While TODDD™ is soft and flexible, unlike soft contact lenses, it doesn’t contain appreciable water and avoids the surface drying and resulting deposits that irritate and deter many contact lens wearers. In recognition of the potential benefits and their developmental progress, the company’s founders have been awarded three National Institutes of Health (NIH-SBIR) grants for the TODDD™ technology totaling $2.5 million.

TODDD™ has issued patents in major markets and has been successfully tested in safety studies, animal trials with drugs and without drug in humans.

Amorphex is seeking to fund small, 30 - 40 subject, human clinical trials of TODDD™ delivering timolol, prostaglandin and both drugs simultaneously. This funding will also support pre-clinical development of TODDD™ for ocular allergy and inflammation applications.  These milestones will drive dramatic increases in valuation and corporate partner interest.

Antibody Solutions is a premier developer of therapeutic, diagnostic and critical reagent antibodies. Our platforms include human antibodies from transgenic OmniRats™, Hybridoma Libraries™, and high-throughput flow-cytometry screening of cell-associated targets. We provide full technical support and project management with all services performed in the USA. 

apceth is a privately held German Biotech company focused on the development and clinical implementation of innovative biopharmaceuticals based on cell and gene therapy in the field of oncology.

Enabling platform technology for genetic modification of mesenchymal stem cells (MSC) to be used as drug shuttle to target tumors or other areas of interest.

Clinical development:

phase I with modified MSC in gastro-intestinal tumors completed (12/2014)

phase I/II with MSC for vascular disease completed

strong clinical pipeline based on genetic modification of MSC

Implementation of allogeneic cell bank system to accomodate off-the-shelf production of cell-based pharmaceuticals.

Strong network and IP,

interesting preclinical pipeline addressing oncology, lung disease, inflammation.

Secure financing by German Family Offic. Looking for partner/ cofinancing for ongoing clinical development (phase II/III)

Aperiomics, Inc. is a next generation sequencing service company with a mission to detect virtually any pathogen from any clinical, agricultural, or environmental sample.  This service platform uses a combination of next-generation sequencing and advanced bioinformatic data analysis to identify pathogens in various samples.  Aperiomics’ proprietary service platform focuses on pathogens of public and animal health importance, satisfying the increasing need for more robust and more efficient next-generation sequencing data analysis.

The impact of Aperiomics’ technologies is broad due to our unique approach to pathogen detection. Instead of blindly probing for a proverbial ‘needle in a haystack’, Aperiomics’ approach analyzes the entire ‘haystack’ using next-generation sequencing and harnessing the power of bioinformatics to identify all ‘needles’. This approach is transformative compared to current pathogen detection methods. Aperiomics’ proprietary service, Absolute*NGS Pathogen Detection Platform, screens samples (clinical, environmental, etc.) for the presence of any microbe (fungal, viral, bacterial, eukaryotic parasite) – including pathogens that have never before been identified. This platform technology has broad application across diverse markets such as health care, agriculture, environmental, industrial, and veterinary testing.

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

Did you know that 10-15% of LASIK patients are turned away due to inadequate eye measurement equipment?  This laser refractive eye surgery market has a crying need for the next generation measurement tool now to capture these additional patients and improve on existing procedures and outcomes.

Did you know that ophthalmologists suffer significant measurement problems in accurately predicting the ELP (Effective Lens Position) in cataract surgery/Intra-Ocular Lens (IOL) procedures?

The ArcScan Artemis-3 system addresses both of these market needs and more.

ArcScan has already raised all funding needed ($3 million) to enter the laser refractive surgery market, with product introduction expected in 12 months.

The ArcScan Series A Preferred funding round of $3 million currently has $1 million available to investors from now through February, 2015, or until sold-out, whichever occurs first.

ArcScan is attending the RESI conference to raise the final $1,000,000 in Series A Preferred share subscriptions, which will allow us to accelerate entry into the large cataract surgery/IOL market and nearly double the size of the business.

Please request a meeting at RESI or contact ArcScan CEO Andy Levien for an executive summary and further investment details.

Arcus Ventures was founded in 2007 and is based in New York City. Arcus Ventures is currently investing from its second fund, which had a first close of $36m in 2014 and is targeting a raise of $100m. The firm typically invests $2-5 million. Arcus invests primarily in the USA but is also open to considering opportunities in Canada.

Armune BioScience is a medical diagnostics company formed to develop and commercialize unique technology for diagnostic and prognostic tests for prostate, lung and breast cancers. The technology is unique because it utilizes autoantibodies created by the body’s own immune system to detect cancer at an early stage. When the immune system recognizes a cancer antigen it creates an autoantibody to the antigen which is replicated by the immune system. Armune’s technology can be used to detect these autoantibodies in serum.

Early detection and prognosis of cancer is critical not only in selecting appropriate treatment protocols, but also in increasing 5-year survival rates among cancer patients. Cancer detection in early stages is typically performed by detecting cancer-specific serum antigens. Unfortunately, cancer serum antigens are present at very low levels in early stage disease. Also, a single detectable cancer antigen may not be present in all patients due to heterogeneity of the disease and therefore multiple biomarkers are needed. Detection of serum autoantibody responses to tumor antigens provides more reliable serum marker(s) for cancer diagnosis. Serum autoantibodies are more stable than serum antigens and may be more abundant than antigens, especially at low tumor burdens characteristic of early stage cancer. The technology does not detect cancer per se, but looks for the immune response to cancer.

Armune’s initial focus is on a prostate cancer diagnostic test. The PSA (Prostate Specific Antigen) test is currently used as a prostate cancer diagnostic test and it has good sensitivity (~86%), but very poor specificity (20 to 30%) resulting in high false positive rates (70 to 80%) and many unnecessary biopsies and costs.

Artery Therapeutics is a San Francisco Bay Area based translational biotechnology company with worldwide collaborations. Artery's novel peptide library derived from Apolipoprotein E shows promising results in various animal studies for diseases such as Alzheimer's disease, Diabetes mellitus, and Acute Coronary Syndrome.